TCGA-E2-A1IE-01A-11R-A13Q-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 79
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.300
- DNA_REPAIR+0.290
- E2F_TARGETS+0.280
- MITOTIC_SPINDLE+0.270
- ESTROGEN_RESPONSE_EARLY+0.240
- OXIDATIVE_PHOSPHORYLATION+0.240
- ADIPOGENESIS+0.210
- PEROXISOME+0.200
- HEME_METABOLISM+0.170
- BILE_ACID_METABOLISM+0.160
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.620
- ALLOGRAFT_REJECTION-0.610
- INTERFERON_ALPHA_RESPONSE-0.580
- INFLAMMATORY_RESPONSE-0.540
- IL6_JAK_STAT3_SIGNALING-0.520
- TNFA_SIGNALING_VIA_NFKB-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- COMPLEMENT-0.380
- IL2_STAT5_SIGNALING-0.370
- KRAS_SIGNALING_UP-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-C8-A26Z-01A-11R-A16F-07 | — | B | 0.902 |
| 2 | TCGA-E2-A156-01A-11R-A12D-07 | — | B | 0.895 |
| 3 | TCGA-B6-A0IC-01A-11R-A034-07 | — | B | 0.892 |
| 4 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.880 |
| 5 | 20040104.LumB | — | B | 0.879 |
| 6 | TCGA-E2-A155-01A-11R-A12D-07 | — | B | 0.877 |
| 7 | sclc2008_S40.txt | — | cohortSC | 0.872 |
| 8 | TCGA-AO-A0JI-01A-21R-A056-07 | — | B | 0.872 |
| 9 | TCGA-E9-A1RE-01A-11R-A157-07 | — | B | 0.871 |
| 10 | TCGA-BH-A0HW-01A-11R-A034-07 | — | B | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.090 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.090 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.020 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.010 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.010 | Idelalisib | — uncovered |